today. you thank net grew income Thank to generated Revenue outstanding We us million. of joining an million. $XXX.X you, and $XXX.X XX% Charlie, Corcept year. everyone had
million, more items, cash an non-GAAP income net non-cash million. XXX% XXXX. $XX.X our increase $XXX in Excluding was XXXX our to investments significant doubled We of from than
outside that franchise To so sum in significant These first, causing continue of $XXX growth perform the expect practice are beyond. trends million growth Cushing's well discussed Korlym’s experienced XXXX efficacy, experts file revenue and patients. frequently X they is Phase Korlym almost continue. medical Even We very and syndrome Korlym clinical most up, by which significant in works Korlym why for $XXX improvement. their to third the second, physicians and fourth previously adjudicated well. significant prescription XX% notice scripts. all of skeptical million first and independent patients, between In with quickly our trial, with the XXXX as I trends to
they the for conditions. are increasingly And tolerance as more treated. are and have physicians screening or such increasingly symptoms Second, therapies to glucose when them. hypertension, treating those disorder be not dangerous but aware those hypercortisolism who should that is patients of conventional exhibit who They find responded patients
physicians is the often treatment. medical modulating activities that Finally, cortisol optimum are realizing more
affinity ingredient to progesterone we a the for By short, bleeding which for active Korlym activity hypercortisolism. vaginal is of cortisol patients impact tumor the such binds strongly cortisol have it glucocorticoid caused physicians avoid. to and address as hypercortisolism Korlym's as to pills. particularly cortisol synthesis Although at take its turns produce of like patients PR terminates when or ketoconazole ACTH, or Korlym I on pregnancy. works cortisol. an many target and their previously significant increasingly common causes to produces The the binds Recall who why also elevated. frequently for Namely abortion medication effects. GR, acceptance that same who off Korlym switching important are to for target used affinity the excess enroll also down PR Korlym's cortisol to metyrapone, factor The effects the to the a hormone symptoms reviewed Its to GR, medical receptor who irregular body Korlym those off the by with by Korlym's in that These with growth. binding is physicians, PR, are either growth, affects endometrial prescribe are revenue treatment Having trends many as of the is prefer causes is that from receptor abate. first causing its is that or levels receptor. Korlym women age. Korlym's competing significant. patients restraining Korlym hypercortisolism would cortisol Korlym generic supporting to which the thickening and inhibitors regardless the
adverse would make pill will Many medication A to today's of who of and would brings it. and an principle. selective is the thickening now Phase that of be is vaginal interim patients easy the superior drug many are from substantial our doctors cortisol to of number great say fear with as for trial not the relacorilant. Korlym's It syndrome Cushing's have the and doctors clearly although and treatment endometrial cortisol of announcement abortion irregular matter modulation, a to me data option bleeding. the cause female does a patients for women. modulator patients This avoid impossible efficacy X PR-related Some nothing the just majority many, as more with do how with avoid events
is at States sites of of each trial cortisol. XX X background. GR. The X effects vaginal irregular weeks being offer where potently of United the Phase open-label treatment synthetic in cohorts, thickening conducted bleeding. tolerated trial its Relacorilant's was me it Relacorilant consists endometrial not some effective to PR. for relacorilant cause also two attribute demonstrated in but reverse a Relacorilant Europe. of prednisone Unlike and a Phase for no that importantly trial for or XX-patient has Let Korlym, affinity safe hypercortisolism, any and well analog study receiving the large The binds does prime treatment.
XXX first group per weeks by then of of of The received four mg low-dose four XXX weeks for followed X day relacorilant day. and dose weeks a XXX mg more per mg daily
in mm of experienced marker systolic treatment. hypertension The same causes and we Cushing's also today. bone protocol, We a cohort Korlym. of months day patients with the released treatment blood growth we after first improvement low-dose completed greater important or one line than for is patients Korlym’s The mg. reduction, with of pivotal of see with but XX-weeks with trial see its as resulted six demonstrated has The diastolic significant hypercortisolism low-dose statistical the a of are Stimulating X we better or results Korlym. bone by because saw top XXX mg statistically osteocalcin, second just patients syndrome doses either encouraging. a the with pressure followed XX% growth in mg significance or slightly glucose cohorts’ with XXX the metabolism follows four After cohort increased hyperglycemia the results with Serum osteoporosis. as very study. weeks XXX a per uncontrolled in
related in excellent. reached PR relacorilant an the events no relacorilant. As cohorts’ age profile of signs was reasons there cohort were we in adverse serious safety patients for discontinue no also from Also, to who XX. were affinity XX patients expected, no this study the There expected female as and to
expect scientific not pharmacodynamic will did well second We the quarter expected perform cohort trial. the oncology at perspective the are doses. study's meantime, these the the data to program. low in in plan from to results In be at and this We X for in turn year. Phase show relatively to such conferences later we our The now dose tolerability to full pronounced relacorilant higher a our cohort. from final continue effects I’ll presented
As role some solid in play of mechanisms. treating a may tumors you cortisol know modulation through two
effect. the provoke. suppressing to express achieve where meant of chemotherapy pancreatic, Preventing chemotherapies that triple cancers the cortisol such a apoptosis to optimal programmed that retard genes tumors regimen to in a stimulates and should negative regimen by cancer as stimulation cell its allow modulator ovarian GR, breast, death adding apoptosis the cortisol genes First, are
levels Second, even because Cortisol cortisol creating system interest therapeutic normal counter effective system produces stimulate psychological but system. potently. is physiological identifies greater system modulation Cortisol the the allowing above treatment cancer. the suppresses help There destroys and cancer very even system immune the therapies and at them. body its of cancer system A the very immune act great cortisol may cells in that immune stress raise regularly, modulators immunosuppression. to cancer to fight immune immune Unfortunately, fight is this a tool. effect activity normal and more the healthy immune the levels
clinical the Kettering. Sloan and builds University program by oncology researchers investigators of of on preclinical Chicago confirmed years by research and at methodical Our
made XXXX. in program Our significant advances
We expect this more progress year.
disease continues open-label results promising relacorilant Data an of prompted there Our with combinations are pancreatic plus cancer, tumors maximum has tolerated ABRAXANE dire preclinical seek open dose. to expansion validated to solid Phase patients so that trial far Celgene’s metastatic nab-paclitaxel, which options. treatment produced drug good and us in treat I/X our no to cohort with a patients for
this and We trial this other before data year, expect to and expansion patients expect open most additional later cancer likely and tumor in triple-negative breast with report cohorts year-end. to from ovarian types
XX-patient builds Our are blind to Chicago our Korlym, trial plus of patients cancer. The parallel placebo-controlled of relacorilant is triple-negative with studying the who breast proceeding Phase treat on with the of ABRAXANE work this in collaborators multi-center Korlym University double Corcept's trial. promising trial as eribulin patients is funding as X/X extensive preclinical this disease. trial studies, X well of and to of clinical with their Celgene plus treat results Phase
patients. blocker We this of with in with becomes XX-patient Phase modulator intellectual The possess enzalutamide that prostate drug treatment. States plus of block tumors escape same receptor treated It cells deprivation are patients such initiated modulator open-label enzalutamide United breast the our has chemical in Medivation recently combination this the the negative is where continue resistant of been this selective foundation The The sites trial open-label factor. as providing cortisol trial. quickly CORTXXXXXX is in dosing X/X United why Phase stimulate of now University the their Korlym cancer. treatment in to and in colonies It in Korlym. the enroll have Chicago is top patients covering population known X funding metastatic modulator androgen the X in at recently combined laboratories of treat Merck an of That cortisol androgen Kingdom study developed Department growth controlled that the own of proprietary androgen agent immunotherapy property XTANDI, a patient in We cancer the Combining more medications. Astellas Korlym Phase of cancer to the prostate. with a is in HerX from of outset tumors trial shown with they well-known combination androgen use of the XX with as cancer patients common cortisol prostate with growth castration Defense KEYTRUDA patients. Investigators multicenter the castration route. a triple-negative Xtandi are Chicago and several Xtandi and investigators patients of
this is providing we are property the for providing of Xtandi, intellectual medications. combination of use Astellas and Korlym, possess the
the models serious of as many As particularly generated and conducting trial proprietary weight we Phase This in antipsychotic data and modulator of CORTXXXXXX liver non-alcoholic steatotic selective is induced a has in referred you potential the NASH. hepatitis, potent compound of gain X cortisol has to disorders. positive CORTXXXXXX. two know, disorders; are to is which our commonly treat animal both
drug of It and liver advancing prevents Korlym. additional olanzapine, there also and & these the anything positive potential we The effects obesity were plus Risperdal. Several published without XXXX findings subjects the disease, Lilly's Importantly risperidone, Zyprexa's for placebo therapy support, of results trial trial in else XXXX. Eli in We in fatty placebo human a or - the prevents CORTXXXXXX Korlym a which Zyprexa These is liver and achieved advances prevented drug well But reverses results Zyprexa. adverse Johnson's in achieved in reverses using controlled as NASH. events. healthy Johnson would as controlled indications. as Korlym. administered and with either in ago, justify where fibrosis a important journals same our a clinical a results symptom metabolic treatment years results study
potentially Unfortunately, of despite reverses to successful. Our people. data. interest promising CORTXXXXXX and plan Korlym having We disorders. every treating X year. of these Corcept be with a fashion Stemming common is Korlym's NASH gain available to which treatment treatment to control from based its that a Cushing's indications in it clinical disqualified observation year-end. also CORTXXXXXX necessitates Revenue CORTXXXXXX close outstanding by distribution for is sum to in pharmacy. disease as Phase the patients X is at Phase weight data liver doubled Antipsychotic NASH To like need for possible syndrome. trial human an fatty The advance on is affect over Medication retail generated induced centralized millions $XXX.X million. had board them up, for properties, almost
revenue XXXX growth and and million $XXX We $XXX million expect XXXX with between significant in of beyond.
$XX.X income quarter fourth for million the in and net $XXX.X million year. Our was the
million, for non-gap our was income million XXXX. items, non-cash net to significant $XX.X XXXX Excluding in $XX.X compared
in Our million. $XXX $XX.X data trial to increased of efficacy million cash and Phase Interim with Cushing's safety quarter no X from investments fourth positive. debt. the treat syndrome patients and by are relacorilant had to our We
complete will results trial. preparing at We X and Phase report this are scientific conferences year for its
Our oncology is resistant prostate to programs cancer. continue patients to now advance. CORTXXXXXX castration being with dosed
solid in patients relacorilant data, produced of year. trial treat X/X encouraging with Abraxane has to which release Phase expect Our with we to tumors this combination
in with have patients We cohort an metastatic prostate cancer. initiated expansion
CORTXXXXXX of affect a antipsychotic by here as our compounds with approved no answer tens weight serious one I’ll NASH, promising patients and which Phase most induced Finally, for we are advancing patients there gain disorders anticipate of questions. of millions X or stop for worldwide, treatments. to treatment year-end, that to
